Who makes Pantoline®?

Pantoline® is developed by Dong-A ST Co., Ltd..

What development phase is Pantoline® in?

Pantoline® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Pantoline®

Dong-A ST Co., Ltd. · FDA-approved active Small molecule Quality 0/100

Pantoline®, marketed by Dong-A ST Co., Ltd., holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Pantoline®
Sponsor	Dong-A ST Co., Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of DA-5204 on Gastroesophageal Reflux Disease (PHASE3)
A Study to Demonstrate the Efficacy and Safety of Motilitone® (PHASE4)
A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results